Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Axon Enterprise Inc (AXON) vs BridgeBio Pharma Inc (BBIO) Price & Performance

Axon Enterprise IncTrade
BridgeBio Pharma IncTrade

Price performance (Past 24H)

Key statistics

Axon Enterprise Inc vs BridgeBio Pharma Inc — how do they compare? Axon Enterprise Inc trades at $618 (market cap $51.69B), while BridgeBio Pharma Inc trades at $83.5 (market cap $16.36B). The key difference: Axon Enterprise Inc is far larger — about 3.2× BridgeBio Pharma Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Axon Enterprise Inc nearer its low. Which is the better fit depends on your goals.

AXONBBIO
Market Cap
$51.69B$16.36B
Sector
TechnologyHealth
52-Week High
$791.62$90.17
52-Week Low
$345.94$47.29
Enterprise Value
$52.83B$18.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Axon Enterprise Inc

Axon Enterprise (AXON) trades at $616.97, up 3.46% in the last 24 hours, showing strong momentum with a bullish technical signal and consistent earnings beats. The stock is near its pivot point of $629, with support at $616 and resistance at $649. Revenue grew 35% year-over-year in Q2 2026, driven by AI and counter-drone offerings, though high valuation multiples like a P/E of 265.13 and P/S of 16.35 reflect premium pricing. Analyst consensus is strongly bullish with an $685 price target, but gross margin compression and elevated multiples pose risks.

Outlook remains positive given robust growth and AI adoption, but investors face valuation risks and margin pressures. The stock offers upside to consensus targets if execution continues, yet any growth slowdown could trigger significant multiple contraction. Key catalysts include Q3 2026 earnings and AI-driven contract expansions.

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.

The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Axon Enterprise Inc

Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.

Read more on AXON

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO